United Laboratories (HKG:3933) unit Zhuhai United Laboratories, Zhongshan Branch's Cefotaxime Sodium for Injection has been approved by China's National Medical Products Administration after it passed the regulator's consistency evaluation of quality and efficacy for generic drugs.
The drug is intended for the treatment of infections caused by susceptible bacteria, including lower respiratory tract, genitourinary tract, and gynecological infections among others, the pharmaceutical company said in a Tuesday filing with the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.